At the time of writing, Evolent Health Inc [EVH] stock is trading at $31.20, up 2.30%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EVH shares have gain 2.87% over the last week, with a monthly amount drifted -9.09%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 22, February 2024, Evolent Announces Fourth Quarter and Full Year 2023 Results. In a post published today on Yahoo Finance, Full year revenue of $1,963.9 million, 45% growth over 2022.
From an analyst’s perspective:
Evolent Health Inc [NYSE: EVH] stock has seen the most recent analyst activity on March 01, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $45. Previously, Barclays started tracking the stock with Overweight rating on January 03, 2024, and set its price target to $39. On December 06, 2023, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $37 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $46 on October 16, 2023. Stephens initiated its recommendation with a Overweight and recommended $40 as its price target on April 12, 2023. Truist started tracking with a Hold rating for this stock on November 01, 2022, and assigned it a price target of $33. In a note dated July 29, 2022, RBC Capital Mkts initiated an Outperform rating and provided a target price of $40 on this stock.
For the past year, the stock price of Evolent Health Inc fluctuated between $23.33 and $36.70. Currently, Wall Street analysts expect the stock to reach $47 within the next 12 months. Evolent Health Inc [NYSE: EVH] shares were valued at $31.20 at the most recent close of the market. An investor can expect a potential return of 50.64% based on the average EVH price forecast.
Analyzing the EVH fundamentals
According to Evolent Health Inc [NYSE:EVH], the company’s sales were 1.96B for trailing twelve months, which represents an 45.40% jump. Gross Profit Margin for this corporation currently stands at 0.23% with Operating Profit Margin at -0.03%, Pretax Profit Margin comes in at -0.1%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.1 and Total Capital is -0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.62 points at the first support level, and at 30.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.88, and for the 2nd resistance point, it is at 32.55.
Evolent Health Inc [EVH] reported earnings per share of $0.23 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.15/share, meaning a difference of $0.08 and a surprise factor of 53.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.3 per share as compared to estimates of $0.07 per share, a difference of $0.23 representing a surprise of 328.60%.
Ratios To Look Out For
It is important to note that Evolent Health Inc [NYSE:EVH] has a current ratio of 1.01. As well, the Quick Ratio is 1.01, while the Cash Ratio is 0.29. Considering the valuation of this stock, the price to sales ratio is 1.83, the price to book ratio is 3.33.
Transactions by insiders
Recent insider trading involved Blackley Seth, Chief Executive Officer, that happened on Dec 05 ’23 when 0.14 million shares were sold. PRESIDENT, McCarthy Daniel Joseph completed a deal on Nov 15 ’23 to sell 11000.0 shares. Meanwhile, Chief Operating Officer Rafferty Emily Ann sold 7900.0 shares on Aug 15 ’23.
